scispace - formally typeset
Z

Ziyang Zhang

Researcher at University of California, San Francisco

Publications -  46
Citations -  5208

Ziyang Zhang is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Medicine & Mutant. The author has an hindex of 15, co-authored 39 publications receiving 3237 citations. Previous affiliations of Ziyang Zhang include Peking University & Howard Hughes Medical Institute.

Papers
More filters
Journal ArticleDOI

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.

David E. Gordon, +128 more
- 30 Apr 2020 - 
TL;DR: A human–SARS-CoV-2 protein interaction map highlights cellular processes that are hijacked by the virus and that can be targeted by existing drugs, including inhibitors of mRNA translation and predicted regulators of the sigma receptors.
Journal ArticleDOI

Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms.

David E. Gordon, +203 more
- 04 Dec 2020 - 
TL;DR: The authors identified shared biology and host-directed drug targets to prioritize therapeutics with potential for rapid deployment against current and future coronavirus outbreaks, and found that individuals with genotypes corresponding to higher soluble IL17RA levels in plasma are at decreased risk of COVID-19 hospitalization.
Posted ContentDOI

A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing

David E. Gordon, +123 more
- 22 Mar 2020 - 
TL;DR: The identification of host dependency factors mediating virus infection may provide key insights into effective molecular targets for developing broadly acting antiviral therapeutics against SARS-CoV-2 and other deadly coronavirus strains.
Journal ArticleDOI

A platform for the discovery of new macrolide antibiotics

TL;DR: A practical, fully synthetic route to macrolide antibiotics by the convergent assembly of simple chemical building blocks, enabling the synthesis of diverse structures not accessible by traditional semisynthetic approaches is presented.
Journal ArticleDOI

Chronic TGF-β exposure drives stabilized EMT, tumor stemness, and cancer drug resistance with vulnerability to bitopic mTOR inhibition.

TL;DR: Long-term exposure to TGF-β promotes stable EMT in mammary epithelial and carcinoma cells, in contrast to the reversible EMT induced by a shorter exposure, and reveals a role for mTOR in the stabilization of stemness and drug resistance of breast cancer cells and position mTOR inhibition as a treatment strategy to target CSCs.